Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 11/20 | 0.42 |
| ▸ | CES1 | P23141 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23502535 | 0.98 | CES2 (0.50) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL23502505 | 0.80 | CES2 (0.44) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL21137757 | 0.80 | CES2 (0.42) | CES2MEN1KMT2AHSD17B10 | |
| SCHEMBL13883932 | 0.80 | CES2 (0.52) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL13883874 | 0.80 | CES2 (0.52) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL8626643 | 0.79 | CES2 (0.55) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL8626646 | 0.79 | CES2 (0.55) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL23502565 | 0.78 | CES2 (0.46) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL28616981 | 0.78 | CES2 (0.53) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL29010402 | 0.78 | CES2 (0.44) | CES2MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CES2 1053/4885LPAR1 576/4885LPAR3 300/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | CES2 1053/4885LPAR1 576/4885LPAR3 300/4885 |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | CES2 1195/4885LPAR1 636/4885LPAR3 336/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | CES2 1053/4885LPAR1 576/4885LPAR3 300/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | CES2 1195/4885LPAR1 636/4885LPAR3 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.